Abstract: Methods are disclosed for inhibiting or disrupting Janus tyrosine kinase 3 (Jak3) dependent function in cells of lymphoid or myeloid origin, especially for blocking proliferation and function of lymphocytes (e.g., T-cells, B-cells). A Mannich base compound, or a derivative or modified compound, is employed which is capable of selectively inhibiting Jak3 while affecting other protein tyrosine kinase activities to a lesser extent or not at all, to provide beneficial effects such as mitigation of transplant rejection and alleviation of allergic responses with fewer side effects than with conventional immunosuppressive agents.

Abstract: Methods are disclosed for inhibiting or disrupting Janus tyrosine kinase 3 (Jak3) dependent function in cells of lymphoid or myeloid origin, especially for blocking proliferation and function of lymphocytes (e.g., T-cells, B-cells). A Mannich base compound, or a derivative or modified compound, is employed which is capable of selectively inhibiting Jak3 while affecting other protein tyrosine kinase activities to a lesser extent or not at all, to provide beneficial effects such as mitigation of transplant rejection and alleviation of allergic responses with fewer side effects than with conventional immunosuppressive agents.

Abstract: Methods are disclosed for inhibiting or disrupting Janus tyrosine kinase 3 (Jak3) dependent function in cells of lymphoid or myeloid origin, especially for blocking proliferation and function of lymphocytes (e.g., T-cells, B-cells). A Mannich base compound, or a derivative or modified compound, is employed which is capable of selectively inhibiting Jak3 while affecting other protein tyrosine kinase activities to a lesser extent or not at all, to provide beneficial effects such as mitigation of transplant rejection and alleviation of allergic responses with fewer side effects than with conventional immunosuppressive agents.

Abstract: The present invention provides a method for treating a subject in need of immunosuppression, comprising administering to the subject an effective amount of a compound having structure (I) wherein R1, R6 and R7 are independently hydrogen, OH, NH2, SH, halogen, C1-C9 linear or branched chain alkyl, alkylmercapto, alkylamino, etc.; wherein R0 and R2 are independently hydrogen, OH, C1-C9 linear or branched chain alkyl, —CR3R3—CH(O)CH2, —CR3R3—CH═CHR4, etc.; wherein R3 and R4 are independently hydrogen halogen C1-C9 linear or branched chain alkyl, etc.; wherein R5 is hydrogen, C1-C9 linear or branched chain alkyl, phenyl, alkylphenyl, dialkylphenyl, alkylmercapto, etc.; and wherein R8 is hydrogen, C1-C9 linear or branched chain acyl, benzoyl, alkylbenzoyl, etc. Also provided are methods of treating autoimmune disease and preventing organ graft rejection using N-acetylardeemin and related compounds.

Abstract: Chimeric MHC Class I molecules having a recipient-type N-terminus, a donor-type alpha-1 helical region, and a recipient-type alpha-2 domain induce tolerance to donor grafts when administered to the recipient at time of transplantation.

Abstract: Carcinoembryonic antigen (CEA) is produced in vitro from the cell lines LS-180 (ATCC No. CL-187), LS-174T (ATCC No. CL-188), and cells derived therefrom. The CEA thus produced can be used as a standard source for radioimmunoassay procedures to determine CEA plasma levels.